CN118922402A - 结晶前列环素(ip)受体激动剂及其用途 - Google Patents

结晶前列环素(ip)受体激动剂及其用途 Download PDF

Info

Publication number
CN118922402A
CN118922402A CN202380024450.1A CN202380024450A CN118922402A CN 118922402 A CN118922402 A CN 118922402A CN 202380024450 A CN202380024450 A CN 202380024450A CN 118922402 A CN118922402 A CN 118922402A
Authority
CN
China
Prior art keywords
crystalline form
lelipag
xrpd
radiation
measured
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380024450.1A
Other languages
English (en)
Chinese (zh)
Inventor
肯尼斯·法尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Therapeutics Corp
Original Assignee
United Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Therapeutics Corp filed Critical United Therapeutics Corp
Publication of CN118922402A publication Critical patent/CN118922402A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/08—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202380024450.1A 2022-02-15 2023-02-14 结晶前列环素(ip)受体激动剂及其用途 Pending CN118922402A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263310469P 2022-02-15 2022-02-15
US63/310,469 2022-02-15
PCT/US2023/013032 WO2023158634A1 (en) 2022-02-15 2023-02-14 Crystalline prostacyclin (ip) receptor agonist and uses thereof

Publications (1)

Publication Number Publication Date
CN118922402A true CN118922402A (zh) 2024-11-08

Family

ID=87578956

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380024450.1A Pending CN118922402A (zh) 2022-02-15 2023-02-14 结晶前列环素(ip)受体激动剂及其用途

Country Status (9)

Country Link
US (2) US12098116B2 (cg-RX-API-DMAC10.html)
EP (1) EP4479374A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025506098A (cg-RX-API-DMAC10.html)
KR (1) KR20240149924A (cg-RX-API-DMAC10.html)
CN (1) CN118922402A (cg-RX-API-DMAC10.html)
AU (1) AU2023222747A1 (cg-RX-API-DMAC10.html)
CA (1) CA3248736A1 (cg-RX-API-DMAC10.html)
IL (1) IL314717A (cg-RX-API-DMAC10.html)
WO (1) WO2023158634A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023158634A1 (en) 2022-02-15 2023-08-24 United Therapeutics Corporation Crystalline prostacyclin (ip) receptor agonist and uses thereof
IL320516A (en) 2022-10-31 2025-06-01 United Therapeutics Corp Methods for treating pulmonary hypertension
US20250282716A1 (en) 2024-03-11 2025-09-11 United Therapeutics Corporation Methods of making ip-receptor agonists

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2945530A1 (de) 1979-11-10 1981-06-04 Chemische Werke Hüls AG, 4370 Marl Harnstoffe mit cyclischen substituenten, ihre herstellung und verwendung als herbizide
JPH03160438A (ja) 1989-11-20 1991-07-10 Konica Corp ハロゲン化銀カラー写真感光材料
CA2036192A1 (en) 1990-02-13 1991-08-14 Nicholas Meanwell Heterocyclic carboxylic acids and esters
CA2085844A1 (en) 1991-12-27 1993-06-28 Nobuyuki Hamanaka Fused benzeneoxyacetic acid derivatives
JPH06329598A (ja) 1993-05-19 1994-11-29 Daicel Chem Ind Ltd エステルの製造方法
DE4318889A1 (de) 1993-06-07 1994-12-08 Bayer Ag Verfahren zur Herstellung von organischen Carbamaten
CA2185104A1 (en) 1994-03-10 1995-09-14 Kiyoshi Taniguchi Naphthalene derivatives as prostaglandin 12 agonists
JPH11269138A (ja) 1998-03-20 1999-10-05 Mitsubishi Paper Mills Ltd 有機塩基発生剤
US6335459B1 (en) 1998-12-23 2002-01-01 Syntex (U.S.A.) Llc Aryl carboxylic acid and aryl tetrazole derivatives as IP receptor modulators
GB9908934D0 (en) 1999-04-19 1999-06-16 Rolic Ag Liquid crystalline compounds
EP1046631A1 (en) 1999-04-19 2000-10-25 Rolic AG Liquid crystalline compounds
US20040048844A1 (en) 1999-10-20 2004-03-11 Bristol-Myers Squibb Pharma Company Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
JP3938689B2 (ja) 2000-03-16 2007-06-27 エフ.ホフマン−ラ ロシュ アーゲー Ipアンタゴニストとしてのカルボン酸誘導体
WO2002055484A1 (en) 2001-01-12 2002-07-18 Takeda Chemical Industries, Ltd. Biaryl compound, process for producing the same, and agent
TWI316055B (cg-RX-API-DMAC10.html) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
WO2003007888A2 (en) 2001-07-20 2003-01-30 Adipogenix, Inc. Fat accumulation-modulating compounds
MXPA04001253A (es) 2001-08-09 2004-06-03 Ono Pharmaceutical Co Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo.
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
TWI293715B (en) 2002-10-10 2008-02-21 Sipix Imaging Inc A method for inducing or enhancing the threshold of an electrophoretic display, an electrophoretic fluid and an electrophoretic display
CN1735598A (zh) 2002-11-11 2006-02-15 拜耳医药保健股份公司 作为ip受体拮抗剂的苯基或杂芳基氨基烷烃衍生物
CA2755297A1 (en) 2003-02-10 2004-08-26 Vertex Pharmaceuticals Incorporated Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes
GB0317498D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Compounds
KR100806603B1 (ko) 2003-09-22 2008-02-29 에프. 호프만-라 로슈 아게 아미노알킬아미드 치환된 사이클로헥실 유도체
JP4402413B2 (ja) 2003-09-29 2010-01-20 財団法人21あおもり産業総合支援センター U字型化合物およびこれを含む液晶組成物
DE102004006785A1 (de) 2004-02-11 2005-09-08 Mayr, Herbert, Prof. Dr. Verfahren zur CC-Bindungsknüpfung zwischen elektrophilen Substraten und TT-Verbindungen in neutralen bis basischen wässrigen oder alkoholischen Lösungsmitteln ohne den Einsatz einer Lewis- oder Protonensäure
CA2576971A1 (en) 2004-08-20 2006-03-02 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
JP2006083085A (ja) 2004-09-15 2006-03-30 Kyowa Hakko Kogyo Co Ltd 二環性ピリミジン誘導体の製造法およびその合成中間体
JP4792731B2 (ja) 2004-11-12 2011-10-12 Dic株式会社 重合性液晶組成物及び当該組成物の硬化物
WO2007051255A1 (en) 2005-11-04 2007-05-10 The University Of Sydney Process for the preparation of compounds containing an azacyclic ring system
JP2007161867A (ja) 2005-12-14 2007-06-28 Toyo Ink Mfg Co Ltd インキ組成物
AU2007249827A1 (en) 2006-05-09 2007-11-22 Colorado State University Research Foundation Methods for treating blood disorders
US8895776B2 (en) 2008-03-18 2014-11-25 Arena Pharmaceuticals, Inc. Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
EP2367797A1 (en) 2008-11-26 2011-09-28 Arena Pharmaceuticals, Inc. Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
PT2370413E (pt) 2008-12-08 2015-10-23 Arena Pharm Inc Moduladores do recetor da prostaciclina (pgi2) úteis para o tratamento de distúrbios relacionados com o mesmo
EP2480526A1 (en) 2009-09-23 2012-08-01 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of pgi2 receptor agonists
KR102441249B1 (ko) 2014-10-23 2022-09-08 아레나 파마슈티칼스, 인크. Pgi2 수용체 관련 병태의 치료 방법
IL266518B2 (en) 2016-11-10 2026-05-01 Arena Pharm Inc Methods for treating pulmonary hypertension with combinations of relinfag and other substances
IL268997B2 (en) 2017-03-01 2023-09-01 Arena Pharm Inc Preparations containing pgi2 receptor agonists and processes for their preparation
EP3664792A1 (en) 2017-08-07 2020-06-17 Arena Pharmaceuticals, Inc. Methods of treatment
US12433865B2 (en) 2018-05-16 2025-10-07 Arena Pharmaceuticals, Inc. Compositions comprising PGI2-receptor agonists and processes for the preparation thereof
CN112638865B (zh) * 2018-09-06 2022-07-26 广东东阳光药业有限公司 药物共晶体及其制备方法
WO2023158634A1 (en) 2022-02-15 2023-08-24 United Therapeutics Corporation Crystalline prostacyclin (ip) receptor agonist and uses thereof
CA3245146A1 (en) 2022-03-17 2023-09-21 United Therapeutics Corporation RALINEPAG MEDICATIONS AND THEIR USES

Also Published As

Publication number Publication date
EP4479374A4 (en) 2026-07-01
KR20240149924A (ko) 2024-10-15
US12098116B2 (en) 2024-09-24
JP2025506098A (ja) 2025-03-07
EP4479374A1 (en) 2024-12-25
WO2023158634A1 (en) 2023-08-24
IL314717A (en) 2024-10-01
CA3248736A1 (en) 2023-08-24
AU2023222747A1 (en) 2024-08-22
US20240409503A1 (en) 2024-12-12
US20230406815A1 (en) 2023-12-21

Similar Documents

Publication Publication Date Title
US12098116B2 (en) Crystalline prostacyclin (IP) receptor agonist and uses thereof
EP1313714B1 (en) Valsartan salts
EP1549640A2 (en) 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
TW201444786A (zh) 雙環化合物
RU2382648C2 (ru) Фармацевтический состав карбоксамидных ингибиторов интегразы вич, содержащий композицию с контролируемой скоростью высвобождения
CN114007689B (zh) 心肌肌钙蛋白活化剂的多晶型物和共晶体
WO2024138190A1 (en) Crystalline forms of a lpa1 antagonist
WO2023244562A1 (en) Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1- yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
US20190292192A1 (en) Methanesulfonate polymorph of 5-type phosphodiesterase inhibitor and preparation method and applications thereof
WO2022236139A1 (en) Crystalline forms of n-{3-[(1s)-1-{[6-(3,4-dimethoxyphenyl)pyrazin-2-yl]amino}ethyl]phenyl}-5-methylpyridine-3-carboxamide and related products and methods
US20160122274A1 (en) Salts of Sitagliptin, Process from the Preparation and Pharmaceutical Composition Therefore
US12569440B2 (en) Solid formulation of a 1,2,4-oxadiazole derivative
WO2019032631A1 (en) Oxime ether compounds
CA3171894C (en) CARBOXYLIC ACID COCRISTALS (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOLE-2-YLCARBAMOYL)CYCLOPENTANE
CN102770416A (zh) 美他沙酮共晶体
JP7517705B2 (ja) フロピリミジン化合物の塩および結晶形ならびにその医薬用途
WO2024131850A1 (zh) 氟取代的吲唑化合物的晶型及其用途
WO2024126630A1 (en) Purine nucleoside phosphorylase inhibitors for the treatment of metabolic syndrome and associated conditions
EA044681B1 (ru) Полиморфы и сокристаллы активатора кардиотропонина
WO2019072130A1 (zh) 一种1,2,4-三氮唑类化合物
HK1240925A1 (en) Salt of dicarboxylic acid compound
HK1055963B (en) Valsartan salts

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination